These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 25999327)

  • 1. Effects of GnRH analogue treatment on anterior pituitary hormones in children with central precocious puberty.
    Kendirci HN; Ağladıoğlu SY; Önder A; Baş VN; Çetinkaya S; Aycan Z
    J Pediatr Endocrinol Metab; 2015 Sep; 28(9-10):1145-51. PubMed ID: 25999327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Levels of Thyroid Stimulating Hormone and Luteinizing Hormone Are Decreased in Girls with Central Precocious Puberty after 12-Month GnRH Agonist Treatment.
    Kim YJ; Chung LY; Kang E; Nam HK; Rhie YJ; Lee KH
    Tohoku J Exp Med; 2020 Nov; 252(3):193-197. PubMed ID: 33087637
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effectiveness of depot gonadotropin-releasing hormone analogue in the treatment of children with central precocious puberty.
    Clemons RD; Kappy MS; Stuart TE; Perelman AH; Hoekstra FT
    Am J Dis Child; 1993 Jun; 147(6):653-7. PubMed ID: 8506834
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Irreversible increase of serum IGF-1 and IGFBP-3 levels in GnRH-dependent precocious puberty of different etiologies: implications for the onset of puberty.
    Belgorosky A; Rivarola MA
    Horm Res; 1998; 49(5):226-32. PubMed ID: 9568807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in body mass index during gonadotropin-releasing hormone agonist treatment for central precocious puberty and early puberty.
    Lee HS; Yoon JS; Roh JK; Hwang JS
    Endocrine; 2016 Nov; 54(2):497-503. PubMed ID: 27444748
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Two-year results of treatment with depot leuprolide acetate for central precocious puberty.
    Neely EK; Hintz RL; Parker B; Bachrach LK; Cohen P; Olney R; Wilson DM
    J Pediatr; 1992 Oct; 121(4):634-40. PubMed ID: 1403402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overnight levels of luteinizing hormone, follicle-stimulating hormone and growth hormone before and during gonadotropin-releasing hormone analogue treatment in short boys born small for gestational age.
    van der Kaay DC; de Jong FH; Rose SR; Odink RJ; Bakker-van Waarde WM; Sulkers EJ; Hokken-Koelega AC
    Horm Res; 2009; 71(5):260-7. PubMed ID: 19339790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of gonadotropin-releasing hormone analog on ovarian reserve in children with central precocious puberty.
    Tao Y; Si C; Li H; Han J; Hou H; Yang M
    Ann Palliat Med; 2020 Jan; 9(1):53-62. PubMed ID: 32005063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 levels in children with precocious puberty treated with gonadotropin-releasing hormone analog without or in combination with cyproterone acetate.
    Verrotti A; Ferrari M; Sabatino G; Morgese G; Chiarelli F
    Gynecol Endocrinol; 1997 Aug; 11(4):243-50. PubMed ID: 9272420
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Use of Morning Urinary Gonadotropins and Sex Hormones in the Management of Early Puberty in Chinese Girls.
    Zhan S; Huang K; Wu W; Zhang D; Liu A; Dorazio RM; Shi J; Ullah R; Zhang L; Wang J; Dong G; Ni Y; Fu J
    J Clin Endocrinol Metab; 2021 Oct; 106(11):e4520-e4530. PubMed ID: 34160619
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Growth outcome during GnRH agonist treatments for slowly progressive central precocious puberty.
    Massart F; Federico G; Harrell JC; Saggese G
    Neuroendocrinology; 2009; 90(3):307-14. PubMed ID: 19641297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thyroid outcome during long-term gonadotropin-releasing hormone agonist treatments for idiopathic precocious puberty.
    Massart F; Harrell JC; Federico G; Saggese G
    J Adolesc Health; 2007 Mar; 40(3):252-7. PubMed ID: 17321426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Gonadotropin-Releasing Hormone (GnRH) Stimulation Test Before and After GnRH Analogue Treatment for Central Precocious Puberty: Has the GnRH Test been Adequately Simplified?
    Kim MS; Hwang PH; Lee DY
    Indian J Pediatr; 2015 Nov; 82(11):996-1000. PubMed ID: 25956950
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of domestic leuprorelin in girls with idiopathic central precocious puberty: a multicenter, randomized, parallel, controlled trial.
    Li WJ; Gong CX; Guo MJ; Xing J; Li T; Song WH; Luo XP; Wu D; Liang JP; Cao BY; Gu Y; Su C; Liang XJ; Liu M; Wang R; Li FT
    Chin Med J (Engl); 2015 May; 128(10):1314-20. PubMed ID: 25963350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of leuprolide acetate 3-month depot 11.25 milligrams or 30 milligrams for the treatment of central precocious puberty.
    Lee PA; Klein K; Mauras N; Neely EK; Bloch CA; Larsen L; Mattia-Goldberg C; Chwalisz K
    J Clin Endocrinol Metab; 2012 May; 97(5):1572-80. PubMed ID: 22344198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolactin secretion before, during, and after chronic gonadotropin-releasing hormone agonist treatments in children.
    Massart F; Parrino R; Placidi G; Massai G; Federico G; Saggese G
    Fertil Steril; 2005 Sep; 84(3):719-24. PubMed ID: 16169408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.